Cero Therapeutics Holdings Inc. Announces Additional Closings of Series D Preferred Stock, Raising Over $3 Million in Private Placement
Cero Therapeutics Holdings Inc. has completed several private placement transactions involving the sale of Series D convertible preferred stock to institutional investors. On June 5, 2025, the company sold 938 shares for approximately $750,400. On June 25, 2025, an additional 2,315 shares were sold for approximately $1,852,000. Most recently, on July 18, 2025, Cero Therapeutics sold 497 shares for approximately $397,600. These transactions were conducted without registration under the Securities Act, relying on exemptions for sales to accredited investors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-065655), on July 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.